Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
Summary
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if subjects meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical treatment study.
Eligible Conditions
- Cancer
- Head and Neck Cancers
- Cervical Cancer
- Non-Small Cell Lung Cancer
- Melanoma
- Ovarian Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Frequency of subjects with TAA expression, HLA typing and HLA loss.
Find a Location
Who is running the clinical trial?
TScan Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
443 Total Patients Enrolled
Dawn Pinchasik, MDStudy DirectorTScan Therapeutics, Inc.
1 Previous Clinical Trials
100 Total Patients Enrolled
Debora Barton, MDStudy DirectorTScan Therapeutics, Inc.
4 Previous Clinical Trials
1,223 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger